I’m a hematologist with specialties in acute myeloid leukemia (AML) and blood and marrow transplant (BMT). I also serve as a clinical instructor at The Ohio State University.
After I received my medical degree from Albany Medical College, I completed my residency and fellowship at Ohio State, and was delighted to be asked to join the staff at the OSUCCC – James. In 2012, I received Ohio State’s Michael R. Grever Award for The Outstanding Clinical Resident in Hematology/Oncology.
My research focus is developing new therapies for AML, using both immune-therapies and small molecules, and Phase I clinical trials. The James is a first class facility where cutting edge therapies are developed everyday. We learn from one another as we share our findings. It’s an honor to work alongside some of the foremost cancer experts in the world and see the progress we’re making toward eradicating this disease.
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 11/21/2019, Dr. Larkin has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.